AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06461624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GPC3 CAR-T
Description: All subjects were intravenous administrated with CBG166.
Study NCT05370430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAFFR-CAR T cells
Description: First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
Study NCT04681079 — intervention group
Intervention type: DRUG
Intervention: albuterol sulfate (MDI)
Description: albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
Study NCT04681079 — intervention group
Intervention type: DRUG
Intervention: albuterol sulfate (nebulizer)
Description: albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
Study NCT05216692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: La Tour Hospital Foot Strengthening Protocol
Description: First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity.
Study NCT05216692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Literature Foot Strengthening Protocol
Description: During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position.
Study NCT05215925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+carboplatin+pemetrexed
Description: HLX07 1500mg q3w+carboplatin+pemetrexed
Study NCT05215925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+docetaxel
Description: HLX07 1500mg q3w+docetaxel
Study NCT05215925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 1500mg q3w
Study NCT06324240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT06324240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06324240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Therapy
Description: Given TMV vaccine ID
Study NCT06087549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block using 0.2% ropivacaine
Description: Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
Study NCT06087549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block using 0.2% ropivacaine
Description: Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
Study NCT06087549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: No erector spinae block and no pericapsular nerve group block
Study NCT05133063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude letter
Description: Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes.
Study NCT05133063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Participants receive the following instructions:~Think of the room you are in.... In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes.
Study NCT01522092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 5mg-20mg, tablet, od, 12 months
Study NCT05783726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
Study NCT05783726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutriscore Label
Description: A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
Study NCT05783726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Peruvian Nutrient Label
Description: A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
Study NCT05783726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline Daily Amount Label
Description: A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
Study NCT05960019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented milk product
Description: This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
Study NCT05960019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented cereal based product
Description: This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
Study NCT05960019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural modification counselling
Description: Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
Study NCT04748237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary computed tomopraphic angiography
Description: CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
Study NCT05206500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotic
Description: FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC >0 and \<10,000
Study NCT05206500 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Next Gen
Description: Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
Study NCT06014762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-CD19CD20-ALLO1
Description: Single weight-based IV administration
Study NCT06014762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Single weight-based IV administration
Study NCT05334836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI for pancreatic fat and liver fat quantitation
Description: MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
Study NCT06448299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: Patients will receive ultrasound guided bilateral oblique subcostal TAPB using 25 mL bupivacaine 0.25% in each side
Study NCT06448299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: Patients will receive ultrasound guided bilateral ESPB at T8 level using 25 mL bupivacaine 0.25% in each side
Study NCT05454839 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Interviewer-administered survey
Study NCT05454839 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Focus group for selected participants
Study NCT04287413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led primary care model for back pain
Description: Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans.
Study NCT04287413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
Study NCT04629248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
Study NCT04629248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
Study NCT04629248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Study NCT04629248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Study NCT04629248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Study NCT05580861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
Study NCT05790954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
Study NCT05673252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
Study NCT05673252 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Description: histopathology findings
Study NCT05118581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided vascular access
Description: Arterial or venous catheterization guided by ultrasound
Study NCT04873284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV
Study NCT04873284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg).
Study NCT04873284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO.
Study NCT05444478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: only microwave ablation for tumor
Study NCT05444478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib (80 mg for body no more than 60kg，120 mg for body weight >60 kg)
Study NCT05874453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye care protocol
Description: The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
Study NCT06152250 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liver Fine-Needle Aspiration
Description: At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy.
Study NCT04731376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard peri-operative care
Study NCT04731376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05329506 — intervention group
Intervention type: OTHER
Intervention: patient population
Description: questionnaires, standard of care
Study NCT06366945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 on weeks 1, 3, and 6
Study NCT06366945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
Study NCT06366945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymeric Micellar Paclitaxel
Description: Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
Study NCT04731376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04731376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
Study NCT06366945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Primary +/- Neck Dissection
Description: Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
Study NCT06366945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy
Description: Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
Study NCT05553782 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: * Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine
Study NCT05618145 — intervention group
Intervention type: OTHER
Intervention: Clinical information
Description: The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
Study NCT04531670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iRaPID
Description: Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
Study NCT04531670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.